Combivir

Combivir is a brand name of lamivudine/zidovudine, approved by the FDA in the following formulation(s):

COMBIVIR (lamivudine; zidovudine - tablet; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: September 26, 1997
  
  Strength(s): 150MG;300MG ^[RLD][AB]

Has a generic version of Combivir been approved?

A generic version of Combivir has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Combivir and have been approved by the FDA:

LAMIVUDINE AND ZIDOVUDINE (lamivudine; zidovudine tablet; oral)

• 
  Manufacturer: TEVA PHARMS
  
  Approval date: May 25, 2011
  
  Strength(s): 150MG;300MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Combivir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Antiviral combinations
  Patent 5,859,021
  Issued: January 12, 1999
  Inventor(s): Cameron; Janet Mary & Cammack; Nicholas
  Assignee(s): Glaxo Group Limited
  Combinations comprising a compound of formula (1) ##STR1## or a pharmaceutically acceptable derivative thereof and an inhibitor of HIV replication, pharmacetical formulations thereof and their use in the treatment of HIV infections.
  
  Patent expiration dates:
  
  
  • May 15, 2012
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Crystalline oxathiolane derivatives
  Patent 5,905,082
  Issued: May 18, 1999
  Inventor(s): Roberts; Tony Gordon & Evans; Paul
  Assignee(s): Glaxo Group Limited
  (-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.
  
  Patent expiration dates:
  
  
  • May 18, 2016
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 18, 2016
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Combivir Consumer Information (Drugs.com)
• Combivir Consumer Information (Wolters Kluwer)
• Combivir Consumer Information (Cerner Multum)
• Combivir Advanced Consumer Information (Micromedex)
• Lamivudine/Zidovudine Consumer Information (Wolters Kluwer)
• Lamivudine and zidovudine Consumer Information (Cerner Multum)
• Lamivudine and zidovudine Advanced Consumer Information (Micromedex)